Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Company Deals

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

Fineline Cube Mar 6, 2026
Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Company Deals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Fineline Cube Mar 5, 2026
Company Deals

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Fineline Cube Mar 4, 2026
Policy / Regulatory

NMPA Removes OCALIVA from GQCE Reference List – Obeticholic Acid Stripped Over Safety Concerns, Benefit-Risk Profile

Fineline Cube Mar 10, 2026
Company Drug

HutchMed Withdraws TAZVERIK from China – Safety Concerns Drive Global Recall of Epizyme/Ipsen EZH2 Inhibitor

Fineline Cube Mar 10, 2026
Company Drug

Fosun Pharma’s HLX316 Wins NMPA Approval – First-in-Class B7-H3 Sialidase Heterodimer Targets Advanced Solid Tumors

Fineline Cube Mar 10, 2026
Company

Shanghai Henlius Biotech Reports 84.0% YOY Revenue Growth in Q3 2023 Financials

Fineline Cube Nov 16, 2023

Shanghai Henlius Biotech Inc., (HKG: 2696) a prominent player in the biopharmaceutical industry, has published...

Company Medical Device

Sino Medical Sciences Technology’s HT Supreme Stent Gains Brazilian Market Approval

Fineline Cube Nov 16, 2023

Sino Medical Sciences Technology Inc., (SHA: 688108) a leading China-based medical device company, has announced...

Company Deals

Gilead’s Kite Expands Partnership with Arcellx for Innovative Cell Therapies

Fineline Cube Nov 16, 2023

Gilead (NASDAQ: GILD), a leading biopharmaceutical company, has announced an expansion of its 2022 partnership...

Company Deals

AbbVie Partners with Sinopharm to Enhance Novel Drug Accessibility and Patient Management

Fineline Cube Nov 16, 2023

US pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a strategic partnership with Sinopharm Group...

Company Drug

Fujian Cosunter’s COVID-19 Therapy GST-HG171/Ritonavir NDA Accepted by NMPA

Fineline Cube Nov 16, 2023

Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a China-based pharmaceutical company, has announced that its...

Company Deals

Astellas Pharma Acquires Propella Therapeutics for $175 Million to Boost Prostate Cancer Treatment

Fineline Cube Nov 16, 2023

Japan’s Astellas Pharma (TYO: 4503) has announced the negotiation of a purchase agreement for US...

Company Deals

Novartis Acquires HDAC6 Inhibitor CKD-510 from CKD Pharmaceutical in a $1.31 Billion Deal

Fineline Cube Nov 16, 2023

Swiss pharmaceutical major Novartis (NYSE: NVS) announced last week that it has struck a deal...

Company Drug

China’s NMPA Accepts EOC Pharma Group’s Filing for Vascepa (Icosapent Ethyl) for Review

Fineline Cube Nov 15, 2023

The China-based EOC Pharma Group has achieved a significant milestone with the National Medical Products...

Company Deals

Eli Lilly Clears Final Regulatory Hurdle with NRC Approval for Point Biopharma Acquisition

Fineline Cube Nov 15, 2023

The Nuclear Regulatory Commission (NRC) of the US has given its approval for the transfer...

Company

Merck KGaA Outlines Expansion Plans for US Healthcare Market with Anticipated 2025 Drug Launches

Fineline Cube Nov 15, 2023

Germany’s Merck KGaA (ETR: MRK), a leading player in the global pharmaceutical industry, has this...

Company Deals

Hubei Topgene Biotechnology and Shanghai Genechem Partner on Drug Toxicological Safety and Clinical Research

Fineline Cube Nov 15, 2023

Hubei Topgene Biotechnology Co., Ltd, a China-based biotechnology company, has entered into a partnership with...

Company Drug

EMA’s CHMP Issues Positive Opinion for Roche’s Tecentriq SC Subcutaneous Formulation

Fineline Cube Nov 15, 2023

The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA)...

Company Deals

PRECEDO Secures Over RMB 100 Million in Financing to Build Living Primary Cancer Cell Bank

Fineline Cube Nov 15, 2023

PRECEDO, a leading cell engineering specialist headquartered in Hefei, has reportedly secured more than RMB...

Company Deals

Yantai Dongcheng Pharmaceutical and Eckert & Ziegler Form Joint Venture for Medical Isotopes

Fineline Cube Nov 15, 2023

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a China-based pharmaceutical company, is poised to...

Policy / Regulatory

China’s National Allied Procurement Office Announces VBP Tender for Medical Consumables and 3D Printing Products

Fineline Cube Nov 15, 2023

The National Allied Procurement Office has released a notification outlining plans for a volume-based procurement...

Company Medical Device

Sansure Biotech Secures CE IVDR Certifications for Chemiluminescence Analyzers in the EU

Fineline Cube Nov 15, 2023

China-based molecular diagnostics specialist, Sansure Biotech Inc., (SHA: 688289), has announced that it has received...

Company Deals

Huadong Medicine Co., Ltd Secures Partnership and Commercial Rights for Yuyan’s Botulinum Toxin

Fineline Cube Nov 15, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has entered into an equity investment and partnership...

Company Deals Digital Hospital

Zeiss Group and China’s Healthcare Cloud Collaborate on Ophthalmic Services in China

Fineline Cube Nov 15, 2023

Germany-based Zeiss Group, a leader in optical systems and optoelectronic product manufacturing, has entered into...

Company Drug

Eli Lilly’s Donanemab on Track for Priority Review in China for Early-Stage Alzheimer’s

Fineline Cube Nov 15, 2023

The China’s Center for Drug Evaluation (CDE) website has indicated that Eli Lilly’s (NYSE: LLY)...

Company

CASI Pharmaceuticals Reports Q3 2023 Results with Mixed Fortunes and Positive Developments

Fineline Cube Nov 15, 2023

China-based CASI Pharmaceuticals Inc., (NASDAQ: CASI) has unveiled its financial results for the third quarter...

Posts pagination

1 … 409 410 411 … 632

Recent updates

  • NMPA Removes OCALIVA from GQCE Reference List – Obeticholic Acid Stripped Over Safety Concerns, Benefit-Risk Profile
  • HutchMed Withdraws TAZVERIK from China – Safety Concerns Drive Global Recall of Epizyme/Ipsen EZH2 Inhibitor
  • Fosun Pharma’s HLX316 Wins NMPA Approval – First-in-Class B7-H3 Sialidase Heterodimer Targets Advanced Solid Tumors
  • Hengrui’s HRS9531 Wins NMPA Approval for CKD Trial – Dual GIPR/GLP-1R Agonist Expands Beyond Diabetes and Obesity
  • Merck KGaA Cuts SpringWorks Hippo Inhibitor and Hengrui PARP1 Program – R&D Pipeline Optimization Ditches €3.7 Billion in Acquired Assets
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA Removes OCALIVA from GQCE Reference List – Obeticholic Acid Stripped Over Safety Concerns, Benefit-Risk Profile

Company Drug

HutchMed Withdraws TAZVERIK from China – Safety Concerns Drive Global Recall of Epizyme/Ipsen EZH2 Inhibitor

Company Drug

Fosun Pharma’s HLX316 Wins NMPA Approval – First-in-Class B7-H3 Sialidase Heterodimer Targets Advanced Solid Tumors

Company Drug

Hengrui’s HRS9531 Wins NMPA Approval for CKD Trial – Dual GIPR/GLP-1R Agonist Expands Beyond Diabetes and Obesity

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.